Good evening, ladies and gentlemen, and welcome to the Third Quarter of 2021 Earnings Conference Call for Tactile Medical. At this time all participants have been placed in a listen-only mode. At the end of the company’s prepared remarks we will conduct a question-and-answer session. Please note that this conference call is being recorded and will be available on the Company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including those identified in the risk factors section of our Annual Report on Form 10-K, as well as our most recent 10-Q filing, filed today with the Securities and Exchange Commission. Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise. This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website. I would now like to turn the call over to Mr. Dan Reuvers, Tactile Medical's President and Chief Executive Officer. Please go ahead, sir.

Thanks, Operator, and welcome everyone to our third quarter of 2021 earnings call. I'm joined on the line by Brent Moen, our Chief Financial Officer. In terms of what we intend to cover this evening, I'll begin with an overview of our third quarter sales performance, along with a discussion of the drivers, trends, and operational highlights we saw during the quarter. Brent will discuss our third quarter financial results in greater detail and review our financial guidance, which we updated in our earnings release this afternoon. I'll then conclude with some additional thoughts on our outlook before we open the line for questions. With that, let's begin with a review of our sales performance. Total revenue for the third quarter increased 7% year-over-year to $52.5 million. Our total revenue growth was largely driven by sales and rentals of our lymphedema products, which increased 5% year-over-year, with sales of our recently acquired AffloVest product contributing approximately two percentage points to our total revenue growth in the third quarter. Sales and rentals of our Flexitouch and Entre systems increased 3% and 23% year-over-year, respectively. Our Flexitouch and Entre systems sales performance in the third quarter of ’21 was softer than we'd anticipated for several reasons. Let me take a moment to walk through the primary factors that impacted our third quarter performance. Flexitouch and Entre sales were impacted by the extended recovery from COVID-19. Heading into the second half of 2021, we'd expected progressive improvements in COVID-related headwinds, continuing the trends we saw in late May and into June. With these expectations as a backdrop, during the third quarter, the resurgence of the Delta variant led to renewed headwinds similar to those that we'd seen earlier in the pandemic. Most notably, at many of the health care facilities we serve, we saw increased patient absenteeism, constraints on treatment capacity and patient throughput, and the renewal of restrictions on rep access to patients and clinicians, limiting our team's ability to conduct in-clinic product demonstrations and challenging our efforts to engage with new clinician customers. While the resurgence of these COVID-related headwinds was seen across our customer base, vascular clinics and other outpatient-based or privately owned practices continued to demonstrate the most resilience, while practices based in hospitals and larger health systems remained more restrictive. The VA continued to be among our most challenging sites of care. As anticipated, many of the VA hospital systems continued to redirect lymphedema patients to their network of outpatient clinics, away from the more concentrated specialist settings. As a result, our VA sales in the third quarter were flat year-over-year and declined 8% compared to the second quarter of ’21. We revised our full-year revenue outlook to account for the softer-than-expected third quarter sales results. Our current expectation is that the operating environment doesn't materially improve over the balance of the year, as well as the impact of fewer product specialists at quarter end than our prior guidance had assumed. Recall that our commercial field team is comprised of product specialists, or full quota carrying sales reps, along with associate product specialists and field support specialists whose priority is to support patient demos and the administrative task of records collection, thus enabling improved productivity within the sales ranks. We entered 2021 with a team of approximately 225 product specialists and associate product specialists with roughly a 50-50 split between the two roles. Consistent with our stated goals for 2021, we promoted approximately 30 of our existing associate product specialists to product specialists to expand the number of sales territories, aiming to end 2021 with a roughly 60-40 split, of which our product specialist headcount would be roughly 140. We've, however, experienced higher than expected product specialist attrition to date. The challenging labor market, compounded by some candidates’ vaccination reluctance, has impacted our ability to recruit, hire, and retain qualified candidates. Specifically, we are down roughly 24 product specialists versus what our guidance for ’21 had assumed. It's worth noting that we grew our lymphedema segment 5% with a smaller selling crew than last year, reinforcing the productivity gains we're seeing from when our model is fully staffed. I'll discuss some of the initiatives we've put in place to mitigate these staffing-related challenges and enhance our hiring efforts, along with assumptions for Q4 later in my remarks. While our commercial team continued to face COVID-related access issues in the third quarter, they were able to partially mitigate them by using virtual solutions to train patients, raise awareness, and expand prescriber adoption. Our team also continued to engage new and existing prescribers that participated in our clinician education events. We hosted 40 medical education programs in the third quarter, reaching more than 1,400 clinician attendees. We've engaged with more than 4,000 clinicians over the first nine months of ‘21. The success of our clinician education efforts, despite the challenges presented by COVID, continues to serve as an important source of expanded awareness and adoption. Three other highlights of note in the third quarter. First, in late September, we announced the enrollment of the first patient in a randomized controlled clinical trial evaluating the effectiveness of our Flexitouch Plus system for the treatment of head and neck lymphedema. This is the largest randomized controlled trial ever conducted for the treatment of lymphedema related to cancer of the head and neck. This trial will compare the effectiveness of Flexitouch to usual care on head and neck cancer survivors. Enrollment was initiated by Dr. Ridner and the team at Vanderbilt University Medical Centre and the study is targeting a total of approximately 250 subjects to be enrolled across six clinical sites. We expect this trial to provide us with the statistical evidence necessary to secure broad reimbursement coverage for our Flexitouch head and neck system, which is the only pneumatic compression device cleared to treat this condition. It's also the kind of evidence generation we expect will continue to differentiate the Flexitouch from other treatment options. We were also pleased to see continued evidence within the medical community of the increasing awareness and recognition of both the prevalence of lymphedema and the need for its effective management. In August, the National Comprehensive Cancer Network, a nonprofit alliance of 31 leading cancer centers, published their updated survivorship guidelines. The updated guidelines added pneumatic compression devices to the list of patient education topics for self-care of lymphedema and encourages therapists to regularly consider pneumatic compression devices for ongoing management of lymphedema at home. This is another important step in addressing the comprehensive needs within the post-cancer care. Finally, on September eighth, we announced the acquisition of the AffloVest respiratory therapy product. This market entry squarely fits our mission to reveal and treat patients suffering from underserved chronic conditions in their homes. It's also consistent with our existing portfolio of clinically proven wearable therapeutic garments with established reimbursement, enabling patients with effective self-care solutions. AffloVest is a wearable vest that treats patients with chronic respiratory conditions, including bronchiectasis, a derivative of COPD, as well as conditions resulting from cystic fibrosis and neuromuscular disorders. AffloVest is the first truly portable high frequency chest wall isolation vest, providing patients with increased mobility. Treatment with the AffloVest has been demonstrated to reduce antibiotic use, emergency room visits, and hospitalizations. Similar to our existing products, AffloVest targets a large and under penetrated patient population. Bronchiectasis is one of the most common respiratory diseases. Of the more than 16 million US patients living with COPD, it’s estimated that over 4 million may be affected by bronchiectasis. Each year, 500,000 adults are diagnosed with bronchiectasis and this figure is expected to grow in the high single digits annually. Based on these estimates, we believe the annual addressable market opportunity for the AffloVest to be as high as $5 billion in the US alone. The AffloVest sales team has achieved impressive market share gains by partnering with respiratory DME companies that are uniquely positioned to leverage their access to providers and patients by featuring AffloVest within their portfolio of complementary products and services for chronic respiratory conditions. In fact, patients that require airway clearance therapy are commonly also in need of oxygen, nebulizers, and non-invasive ventilation, underscoring the merit of being a part of the comprehensive solutions that the respiratory DME channel represents. We also believe that our market development methods of investing in evidence generation and clinical education will be well served in this space. With a universe of approximately 4,000 respiratory DME reps to partner with in the US, we aim to continue this strategy, leading to continued growth in the years to come. Lastly, the acquisition of AffloVest is aligned with our margin expansion goals, with a gross margin profile in excess of 70% and adjusted EBITDA margins of more than 30%. Following the acquisition, we onboarded the 11 member internal AffloVest sales team to ensure an uninterrupted level of support to our respiratory DME partners, and I'm pleased to report that the integration of AffloVest is progressing very well.

Thanks, Dan. Total revenue in the third quarter increased 7% year-over-year to $52.5 million, compared to $49.1 million in the third quarter of 2020. By product category, sales and rentals of our Flexitouch systems increased 3% year-over-year to $44 million in the quarter. Sales and rentals of our Entre systems increased 23% year-over-year to $7.6 million. Sales of our recently acquired AffloVest system contributed approximately $860,000 for the period following the acquisition closing date on September 8, 2021. Total revenue by channel was 68% commercial, 17% Medicare, 13% VA, and 2% durable medical equipment distributors. The latter is a new channel comprised of revenue from our recent acquisition of AffloVest. These figures compared to our total revenue by channel in the third quarter of 2020, in which the commercial, Medicare, and VA channels represented 70%, 16%, and 14% of total revenue. Continuing down the P&L, unless noted, all references to third quarter results are on a year-over-year basis. Gross margin was 70.4% of sales compared to 71.2% last year. Non-GAAP gross margin was 71.8% of sales compared to 71.3% in the prior year. Non-GAAP gross margin excludes non-cash, intangible amortization, inventory write-offs, and non-cash purchase price adjustments related to our acquisition of AffloVest in the current year period. As a reminder, we have provided reconciliations of certain GAAP to non-GAAP measures in our earnings press release. The third quarter operating expenses were $38.3 million, an increase of $5.2 million, or 16%. The year-over-year increase in operating expenses was driven primarily by a 2.7 million or 14% increase in sales and marketing expenses, primarily due to increases in personnel-related compensation expense and travel-related expenses as we returned to hosting in-person regional sales meetings. There was also a $2 million or 16% increase in reimbursement, general and administrative expenses. The increase primarily includes higher occupancy costs, legal fees, and $800,000 of non-recurring transaction-related costs associated with the acquisition of AffloVest. Operating loss was $1.4 million compared to operating income of $1.8 million last year. Non-GAAP operating income was $1 million compared to $2.6 million last year. Income tax expense was $1.9 million compared to an income tax benefit of $800,000 last year. The change was primarily due to changes in our effective tax rate, which were attributable to a change in projected taxable income compared to last year. Net loss was $3.4 million or $0.17 per diluted share, compared to net income of $2.4 million or $0.12 per diluted share last year. Non-GAAP net loss was $1.6 million compared to non-GAAP net income of $3 million last year. Weighted Average shares used to compute GAAP, diluted net income, and loss per share were 19.8 million and 19.7 million shares for the third quarter of 2021 and 2020, respectively. Adjusted EBITDA was $4.1 million compared to $6.2 million last year. On September 8, 2021, we amended our restated credit agreement, adding an incremental $30 million term loan to the $25 million revolving credit facility provided by the restated credit agreement. We borrowed the $30 million term loan on September 8, and utilized that borrowing along with the $25 million under our revolving credit facility and cash on hand to fund the AffloVest acquisition. As of September 30, 2021, we had $22.4 million in cash and cash equivalents and $52.5 million of outstanding borrowings on our revolving credit facility compared to $47.9 million in cash and cash equivalents and no outstanding borrowings as of December 31, 2020. The change in cash quarter-to-quarter, excluding the acquisition of AffloVest and related financing, was approximately $2 million. Turning to a review of our 2021 outlook, which we updated in our earnings press release this afternoon. We now expect full year 2021 total revenue in the range of $203.5 million to $206 million, representing growth of approximately 9% to 10% year-over-year, compared to total revenue of $187.1 million in 2020. Our updated total revenue guidance range includes contributions from sales of AffloVest in the range of approximately $5 million to $5.5 million from the closing date of September 8 to December 31, 2021. This revised outlook compares to our prior revenue guidance range of $216.3 million to $224.5 million, or 16% to 20% year-over-year growth. Note that our prior guidance range was updated as part of our second quarter financial results report in August and did not include the contributions from our acquisition of AffloVest from the closing date of September 8 to December 31, 2021. By product, our updated 2021 total revenue guidance range assumes sales of our Flexitouch systems increased approximately 5% to 6% year-over-year. Sales of our Entre systems increased approximately 14% to 19% and contributions from sales at AffloVest are expected to be in the $5 million to $5.5 million range. For modeling purposes, for the full year, we expect our gross margin to be in the low 70% range. Our adjusted EBITDA margin to be in the range of 6% to 8%.

With that, I'll turn the call back to Brent for some closing remarks.

Thanks, Dan. So broadly speaking, our updated guidance today reflects a revised outlook for the operating environment during the second half of 2021. Our updated guidance also reflects the changes within the composition of our commercial team, specifically a smaller number of product specialists through the fourth quarter. Our revised outlook for the operating environment, and for the composition of our field commercial team, are expected to be partially offset by the contributions from the AffloVest. Let me share a bit more on our assumptions driving our revised guidance for Flexitouch and Entre sales in more detail. With respect to our expectations for business disruption related to the impact of the Delta variant, our prior guidance had assumed progressive improvements in COVID related headwinds throughout the second half of 2021. We now expect the primary COVID related headwinds that we experienced in the third quarter to persist into the fourth quarter, postponing our pace of recovery. The second half impacts of the Delta variant coupled with our lower selling headcount are the key contributors to the revision in our Flexitouch and Entre revenue guidance. Specifically, we expected to end 2021 with approximately 225 direct sales reps, with a roughly 60-40 split in favor of product specialists. Given the higher than expected attrition of product specialists that we saw during the third quarter, we have 24 fewer product specialists than our guidance for 2021 had contemplated. As we've said in the past, our fully tenured sales reps contribute well above a million dollars per year on average and significantly higher when supported with an FSS. So the impact of this attrition offset, partially by the improved productivity from our expanded team of field support specialists, is responsible for the balance of our Flexitouch and Entre revenue guidance change. Finally, the low end of our Flexitouch and Entre revenue guidance contemplates the potential for some additional sales force attrition related to our internal vaccine efforts during the fourth quarter. We've seen increased access issues from both clinicians and patients. We're also mindful of our obligations within the recent executive orders. As a result, we've conveyed expectations of full vaccination by year end, in an attempt to restore optimize customer access, address our executive order obligations and ensure the safety of our patients, customers, and employees. While we believe this is in the long-term interest of all of our stakeholders, it introduces some uncertainty in the short term, as some employees have voiced reluctance to get vaccinated. To address these challenges, we’re focused on investing to enhance our sales rep retention efforts, bolster our internal recruiting resources, and increasing our hiring incentives, especially for territories that have been more difficult to staff. To be clear, we see the headwinds affecting our business in the second half of 2021 as impactful but transitory and continue to believe that we're incrementally better positioned for long-term success and value creation. Given the increasing awareness and consensus within the medical community of the prevalence of lymphedema and the importance of effective treatment, along with our product development initiatives, advancing and positioning our portfolio with improved patient solutions and the addition of AffloVest to our portfolio, which expands our addressable US market opportunity to over $10 billion per year. With our expanded portfolio of clinically proven products, and a robust product pipeline, we remain excited about our longer-term prospects and look forward to expanding the awareness and treatment options for patients with lymphedema, bronchiectasis, and other chronic conditions as we continue our mission to reveal and treat patients with underserved chronic conditions in the home. I'm appreciative to our employees for enduring a challenging environment and sharing a commitment to making a difference in thousands of patients’ lives. I'd also like to thank our investors and those on today's call for their interest and support Tactile Medical and our mission.

We’ll now open the call for questions.

Hi, guys. This is Drew on for Adam. Thanks for taking the questions. There's an awful lot to unpack here, but maybe you could just help us understand the breakdown of some of the things that packed in the business. So if you had to split out each of the headwinds, whether that be the access issues at your customers, the sales force attrition, the vaccine challenges, all that kind of stuff. How meaningful each of those headwinds on their own as far as contributing to the Q3 shortfall? And then I think when you did the AffloVest deal, it seemed to be messaged as being incremental to the existing guidance you had out there. So maybe you could just help us understand what, if anything, had changed in the business between now and then and just confidence in that improving?

Sure. Let me take a shot at addressing a little bit of the commentary side, and then I'll turn it over to Brent; he can probably walk you through a bit more of a breakdown on the guidance change with some specifics. But in short, the two things that really contributed, as you alluded to in our prepared remarks, were the COVID headwinds and sales staffing. And I'll just offer a little bit of texture on both. As it related to the COVID headwinds, we had modeled and expected progressive improvements continuing in what we saw in Q2. So recall, Q2 we saw improving conditions. At the time, we were expecting to see continued improved conditions throughout the balance of the year, not back to normal, but certainly improving in some of the underlying headwinds that we'd faced as a result of COVID. With the Delta resurgence, we saw a combination of three things that it affected. One was patient throughput, which has continued to be a consequence of COVID since it was introduced. The second was some patient cancellations increased and staffing vacancies were reported to us as well. All of those lead to pressures on the underlying business. One of the interesting sidebars is we were at the AVF or the American Venous Foundation Congress in October. One of the things that was shared there was the results of a survey within their membership that resulted through May had still said that 60% of respondents saw their volumes down 25% or more compared to pre-COVID windows, and that was through May. So that was when we were seeing improvements. I suspect that the Delta influence of the fall would probably have demonstrated a continuation or even an acceleration of that. So those are some of the consequences we saw with COVID. On the staffing side, two things: one, we've continued to see increasing access issues, especially in the larger university systems, the places where we typically find patients that are affected by cancer. Those have been the places that have been more restrictive. And we've had a fair amount of our sales staff that has still been unvaccinated as of October 1, going into the fourth quarter. So we've introduced a vaccine expectation of our teams by the end of this year. Some of them I think are grappling with that. It's certainly a minority, but there's a segment of our population that I think is still reconciling with that. So that, along with just some of the general conditions we've seen in the hiring marketplace, are just something like I've never seen in my career. Being able to find good talent, the quality and number of candidates available is much more limited. I think those are certainly the key contributors that have led to the change. But let me actually turn it over to Brent. I think he can probably walk you through kind of the bridge from our previous guidance to that which we've shared today.

Hi, Drew. So let me just give you a little bit of perspective on guidance. So just as a reminder, our 2021 total revenue guidance is $203.5 million to $206 million, and that includes $5 million to $5.5 million from the acquisition of AffloVest. Our organic revenue range is $198.5 million to $200.5 million, representing a reduction of $18 million on the low end and $24 million on the high end. So just let me take a little bit of time to walk you through some of the drivers of the change in the organic revenue range. So let's start with the low end. So at the $18 million reduction versus our prior guidance, driven by first, as we detailed out in our prepared remarks, we're down approximately 24 product specialists. Dan had done a little math in his commentary there, but on average, a product specialist does about $1 million or more on an annualized basis. So having been down 24 product specialists versus our prior guidance, that certainly has a sizable impact on the second half results, representing approximately one half of the change in the low end of our organic guidance range, or approximately $9 million of that $18 million that I'd mentioned earlier. Second, we've accounted for the potential for additional sales rep attrition in the fourth quarter related to the mandatory vaccination policies. That impact represents approximately $2.5 million to $3 million in Q4. Third, and again, as detailed in the prepared remarks, our prior guidance had assumed progressive improvements in the operating environments in the second half of 2021. We now expect continued headwinds that impact roughly about one third of the change in the low end of our organic guidance range, or approximately $6 million. As you move to the midpoint and the high ends of the range, you'll note that our guidance reflects the larger impact from COVID headwinds, given our prior guidance assumed stronger growth as a result of the improving environment in the second half of ’21. So hopefully, that gives you a little bit of perspective on the three primary drivers impacting our modification to guidance.

Yeah, very helpful. Thank you. And just to put a finer point on it, I think what people are struggling to really understand is when you strip out COVID, you strip out the staffing shortage noise. Now, do you think your core lymphedema business can still grow in that call it 15% to 20% range? And given the current state of the COVID environment, how long do you think it will be until you can get back to those levels?

Yeah, I think it's a fair question. I don't mean to be curt, but I think that our ability to predict when COVID will subside has clearly been tested. So I'm not sure that that's an easy one to answer. But we certainly at this point expect that this continues to be transitory. I think when you contemplate the two changes in our guidance, one is very much driven by the COVID circumstance, and the other one by staffing. Both of these should be transitional kinds of things. I think it certainly points in my mind that recovery gets pushed out a bit into ’22. That said, to your broader question, what does it say about the underlying market? I still don't believe it says anything. When you think about the durable market conditions, the TAM on both the lymphedema and the respiratory space that we're now participating in are immense and the level of penetration is still very small. So there's nothing that's changed in the underlying market. I think when you couple that with the growing awareness that we're continuing to see of the recognition of the importance of treatment, I think payer relation opportunities for us to continue to improve market access, we've got a robust product development pipeline underway right now that's richer, I think, than perhaps any time in the company's history. Some of the evidence in the market development tailwinds, I think all of those speak to an enduring opportunity for us. So we don't think that this is necessarily a referendum on the space that we're in, but admittedly, a disappointment for us in where we sit at this point in the year.

Hey, good afternoon, guys. Thanks for taking the questions. I'm hoping to dive in a little deeper, based on the prior comments that you made. So maybe on the sales repetition side, just to start there, theoretically while short-term will have some sort of an impact for probably at least a couple of quarters. So I guess, to kind of put a finer point on it, is there a time period at which point that does recover whether it's mid ’22 or beyond? And does that kind of pressure the underlying business, let's say for the first half of ’22, before you kind of get to that more normalized double-digit plus growth rate as we move on throughout the year?

Yeah, Margaret. Hi, it’s Brent. I can provide a little bit of perspective on that. Certainly, sales reps have a big impact on our overall growth rates, for sure being down 24 at the end of the third quarter certainly has an impact in 2021, but also in 2022. We believe that we can – by the end of Q1 should be back in hopefully, the same zone that we expected to be at the end of the third quarter. So it'll be a fairly sizable effort between now and the end of the first quarter, to make sure that we can find appropriate talent to fill the seats. But nonetheless, our expectation is that as we exit Q1, we'll be back in good stead with our product specialists.

Okay, so does that imply that you'll be closer to that 140 that you had mentioned at the beginning of the call? And will it take a couple of quarters from there for those folks to ramp up? Or how should we think about that I guess? And when can kind of the underlying business, I guess, return to growth?

Yeah, I mean, as you recall, some of the commentary that we've made in the past, product specialists, because they are the senior reps do take a degree of time to get to maturity over the course, and recall most of those product specialists, although we're finding them outside of the organization now come from ranks at the associate product specialist level, but they do take some time to get to maturity. And so if we can get back to the 140 at the end of the first quarter, then you're – yeah, you’re looking for a degree of time for them to mature and get ready and present themselves at the same expected levels that a mature rep is. You're looking towards the middle of 2022 before we see kind of a return to normal.

Okay. And just that – I’m sneaking in one more question. Sorry about that guys. But as we think about kind of the underlying improvements, and you guys spoke to it a bit. Yeah, we're hearing from others that as Delta case volumes have declined, some of the restrictions maybe have loosened. So are you assuming maybe that things might get worse again as we get into the winter months? And then again, as we think about ’22, should we think about that 6 million plus or minus some seasonality start to come back, like you referenced maybe in the second quarter or something? Thanks.

Yeah, I think we're continuing to assume that conditions are probably stable, so they don't necessarily deteriorate but also don't improve from what we saw exiting Q3. I think the other issue that we're trying to reconcile is the access issue. So we continued to see – I mean, we've all seen the number of health care facilities, institutions, both large and small, that have imposed vaccination requirements. Most of the doctors, nurses, and therapists that we call on today have been vaccinated. They have started to extend that expectation to those that interact with them, as well as those that are interacting with patients. And I think that's a reasonable expectation as we work alongside those folks. So that's the same expectation that we've shared with our teams. Between now and the end of the year, which is when we said we expect everyone to be vaccinated. Ongoing access issues are probably going to continue to be a bit uneven until we get our teams on the other side of the vaccination topic. So that's kind of another one that we're doing our best to try and handicap.

Okay, thanks guys.

Thanks, Margaret.

All right. Good afternoon, I want to follow up on some of the other lines of questioning if I could, and just dig in a little bit here. So I just want to understand – I mean, the reps that left in the third quarter, or that were no longer with the organization. Can you characterize how many were kind of high-performing reps over that kind of $1 million average productivity level? And I appreciate that these vaccine mandates can be challenging for employers, but it does seem like a large bolus. And so you did have some changes in leadership in sales. And so is there some component there, beyond, say, the vaccine mandate that is kind of hamstringing you guys on some of these dynamics?

Yeah, I think that – I don't necessarily think that's the case as far as leadership change, but just I’ll be able to share a couple of things that might be helpful. First of all, historically, we have seen product specialist turnover into teams, and associate product specialists, those newer reps, the junior folks, tend to have a higher turnover rate. Those were in the 20s. Year-to-date, we're closer to the low 30s overall on a blend. So we're seeing a higher turnover rate than we have in the past. And then I think just from the math piece, there's a hierarchy of productivity to your point. Tenured reps, who’ve been here over a year and are supported by an FSS, those are clearly the highest producers. Then kind of the hierarchy continues to go notching down to tenured reps without a support person to a newer rep less than a year with an FSS to a newer rep without and then finally to a vacant territory. So these vacant territories have a pretty material consequence when they're vacant; we recognize that productivity certainly is impaired. The dependence, I think, on presence and support, and interaction with patients is quite clear. I think when we look at what the turnover has been, we have seen a higher turnover in some of our product specialists than we historically had. But I think it's also a function of a very dynamic and competitive market. I certainly speak to a number of executives at a number of other companies, it's not a unique challenge. But as we get tenured reps who have been with us and have been good producers in this market, they can be a great target for poachers. We’ve seen some folks that have departed either for hospital sales, sometimes not medical, or perhaps they’ve gone somewhere where they didn't require a vaccination. And while that has been a fairly material one for us, there's about 30% of our sales force that remained unvaccinated as of October 1. That's a pretty significant number. And that's why we're broadening our range as far as what we think the remaining consequence might be. But I also believe that it's the right thing to do. I believe that, in time, especially as we get closer to the end of the year, those that are contemplating their destiny on this decision may also conclude that there's very few safe havens, and there are not many others like us that are not hiring the unvaccinated to be out in patient and customer-facing roles. So we're hopeful that our group will come to that conclusion and continue to serve patients. But there's a variable that still remains open.

Okay. And just looking forward, just following up on Margaret's question. I mean, you're going to need to hire pretty rapidly, obviously, to get back to these levels by the first quarter. What impact, Brent, is that going to have on the P&L? I mean, will we see labor rates start to tick up until we see that down the P&L as we think about it going forward? And then I just have another follow-up.

Yeah, I think you're right, Ryan. There's – it's going to be difficult to predict the pace of hiring. But certainly, our plan is for sales rep hiring to hit the target of 140 product specialists by the end of the first quarter. Obviously, it's dependent on the labor market, but we feel good about where we're at and what we're seeing. And then I think COVID will certainly have an interesting impact as we progress through the fourth quarter and into the first quarter. It'll depend on where market rates are taking direct sales rep compensation levels to have an impact on the P&L. But certainly, we're mindful of that as we progress through Q4 and into Q1. With commissions and some of it, it's fairly variable as we progress through. The other thing that you have to also keep in mind, Ryan, is that the AffloVest acquisition is expected to contribute about $5 million to $5.5 million in 2021. And on a full-year basis, the revenue is expected to be somewhere around $17 million on a pro forma basis. So we expect that to be a nice contributor as we progress through the fourth quarter and into the first quarter. And as I think Dan mentioned in his call, the profitability of the AffloVest business is even better than what our core business is. So we expect that adjusted EBITDA margins, at a roughly about a 30% rate for AffloVest will certainly be beneficial as we progress through Q4 and Q1 as well.

Okay. And then just another one for me, and then I'll hop back in queue. But the blended growth rate in a normalized state you guys talked about kind of being in that mid-teens, maybe 20% growth rate. As I think about the split between all the product categories now, between Flexitouch and Entre and Afflo. Can you just talk about kind of what your expectations are for Flexitouch in a normalized environment? Where you think that can grow relative to some of your other higher-growing assets?

While I think Flexitouch is still capable of being a high-growth asset for sure. One of the things that we've seen, the two most difficult environments that we faced in Q3 as we call it out, were both most directly impacted in the Flexitouch category. So the VA tends to be a Flexitouch source for us. And with the VA business flat, that certainly affected Flexitouch more than any other product in the portfolio. The other place is in the oncology space, where access has been a lot harder for us, especially as we've got an unvaccinated portion of our sales force. And the oncology patients typically end up getting a Flexitouch as well. So both the two segments that we saw impact from COVID headwinds kind of squarely hit Flexitouch more than anything else in the portfolio. That's why we still believe that as COVID conditions start to improve, and our access is restored more universally, I think Flexitouch certainly benefits.

Okay. I’ll hop back in queue. Thank you for taking the questions.

Thanks, Ryan.

Thank you. We are currently seeing no remaining questions at this time. That does conclude our conference for today. Thank you for your participation.

Thank you.

Thank you, operator.